| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
High 18F-FDG-uptake of primary tumor, assessed by pretreatment PET/CT,has indicated poor OS in HNC. We analyzed the relation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin using histoculture drug response assay in HNC. Twenty-eight patients were evaluated. SUVmax and I.I. cisplatin were calculated as 18F-FDG-uptake and in vitro chemosensitivity of cisplatin.Each SUVmax≧10.5 or I.I.cisplatin＜50 could significantly differentiate shorter survival group by OS analyses.I.I.cisplatin of patients with SUVmax≧10.5 was significantly greater. In 19 patients with SUVmax ≧ 10.5, those who received treatment with cisplatin-based chemotherapy exhibited a significant relation with longer OS.Cisplatin has the potential to improve OS for HNC that were predicted as shorter OS by 18F-FDG-PET/CT.
|
